Ireland | Imports and Exports | World | Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
The value of exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Ireland totalled $ 44 billion in 2023. Sales of commodity group 3002 from Ireland decreased by 8.49% in value terms compared to 2022. exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" decreased by $ 4.12 billion (cumulative exports of commodity group 3002 from Ireland amounted $48 billion in 2022)
Exports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" amounted to 20% of total exports from Ireland (cumulative merchandise exports from Ireland totalled $ 212 billion in 2023). The share of commodity group 3002 in total exports from Ireland decreased by 1.24 p.p. compared to 2022 (it was 22% in 2022 and cumulative exports from Ireland were equal to $ 219 billion).
Exports of commodity group 3002 amounted to 62% of total sales of group "" from Ireland in 2023 (the value of exports of commodity group from Ireland amounted to $71 billion in 2023). The share of exports of commodity group 3002 in sales of commodity group from Ireland lowered by 2.16 p.p. compared to 2022 (it was 64% in 2022, and exports of commodity group from Ireland were $75 billion).
Where does Ireland export Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc?
Top export destinations of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" from Ireland in 2023:
- USA with a share of 32% (14.4 billion US$)
- Belgium with a share of 18.9% (8.39 billion US$)
- Netherlands with a share of 16.5% (7.34 billion US$)
- Germany with a share of 8.95% (3.97 billion US$)
- Switzerland with a share of 6.62% (2.94 billion US$)
- France with a share of 3.82% (1.69 billion US$)
- Japan with a share of 2.25% (998 million US$)
- United Kingdom with a share of 1.46% (651 million US$)
- China with a share of 1.44% (643 million US$)
- Canada with a share of 1.01% (451 million US$)
Exports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - from Ireland in 2023 represented by the following main commodity groups:
- 0.173% (77 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
The value of imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" to Ireland totalled $ 7.25 billion in 2023. Sales of commodity group 3002 to Ireland went up by 19.7% compared to 2022: imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" went up by $ 1.19 billion (the value of imports of commodity group 3002 to Ireland was equal to $6.05 billion in 2022)
Imports of commodity group 3002 "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc" accounted for 4.81% of total import flow to Ireland (in 2023, total imports to Ireland amounted to $ 150 billion). The share of commodity group 3002 in total imports to Ireland increased by 0.74 p.p. compared to 2022 (it was 4.07% in 2022 and cumulative imports to Ireland were equal to $ 148 billion).
Imports of commodity group 3002 reached 53% of total imports of group "" to Ireland in 2023 (imports of commodity group to Ireland totalled $13.4 billion in 2023). The share of purchases of commodity group 3002 in total imports of commodity group to Ireland increased by 1.83 p.p. compared to 2022 (it was 52% in 2022, and imports of commodity group to Ireland accounted for $11.6 billion).
Where does Ireland import Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc from?
Top trading partners (import of "Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc") of Ireland in 2023:
- USA with a share of 42% (3.08 billion US$)
- Germany with a share of 12.6% (915 million US$)
- Spain with a share of 7.93% (575 million US$)
- Netherlands with a share of 6.01% (436 million US$)
- Switzerland with a share of 5.95% (431 million US$)
- Belgium with a share of 5.91% (429 million US$)
- France with a share of 5.71% (414 million US$)
- Singapore with a share of 3.91% (283 million US$)
- United Kingdom with a share of 2.87% (208 million US$)
- Korea with a share of 1.25% (91 million US$)
Imports structure of 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc - to Ireland in 2023 represented by the following main commodity groups:
- 0.503% (36 million US$): 300290 - Human blood; animal blood prepared for therapeutic/prophylactic/diagnostic uses; toxins, cultures of micro-organisms (excl. yeasts) & sim. products
